© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Pharmacy
Zynteglo May Herald “New Dawn” of Many Seven-Figure Gene Therapies
August 05, 2022
An OptumRx drug pipeline report highlights Zynteglo, a curative gene therapy treatment for beta-thalassemia, and Skysona, a gene therapy for a cerebral adrenoleukodystrophy. FDA approval decision are imminent for both. Price tags of $2 million are expected.
Researchers to Medicare: Mark Cuban Prices Could Have Saved You $3.6 Billion
June 24, 2022
Harvard researchers calculated that buying 77 generic drugs at prices being charged by Mark Cuban’s online pharmacy prices would have lowered Medicare spending on those drugs from $9.6 billion to $6 billion.
FTC Has Put PBMs, PBM Rebates in its Hot Seat
June 17, 2022
A week after announcing a study of the PBM industry, the Federal Trade Commission announced yesterday that it was stepping up possible enforcement actions targeting the industry's rebate practices. Rebates to exclude lower costs from formularies may constitute commercial bribery under the Robinson-Patman Act, the commission said.
Aduhelm: Great Expectations Fizzle
June 17, 2022
Dogged by controversy, the new Alzheimer’s drug has not fared well since its approval by the FDA a year ago.
FTC Launches Inquiry Into PBM Industry
June 07, 2022
The Federal Trade Commission says its inquiry “will shed light on” clawbacks, potentially unfair audits, rebates and other business practices of the pharmacy benefits management (PBM) industry. Today’s announcement says the commission will be requiring information from the six largest PBMs.
Pfizer, Sidekick Health Launch Digital Therapeutic Aimed at Atopic Dermatitis Market
June 01, 2022
The launch is one of several digital therapeutics partnerships Pfizer has announced in recent months.
The CMS Spend on Accelerated Approval Drugs. Is It Time To Tap the Brakes?
May 27, 2022
Two studies published this week documented the billions that Medicare and Medicaid spend on drugs that have been granted accelerated approval by the FDA based on surrogate end points. A study reported today in JAMA Health Forum found that only 6 of the 22 confirmatory trials used clinical outcomes.
Specialty Pharmacy Controls Limit Patient Access, Fein and Long Explain: 2022 Asembia Specialty Pharmacy Summit
May 04, 2022
In their general session, Adam J. Fein, PhD of Drug Channels Institute, and Doug Long of IQVIA reviewed the current specialty pharmacy space, ongoing trends and future expectations.
Nancy Lurker of EyePoint Pharmaceuticals Addresses Innovations in Eye Care, How to Grow in the C-Suite and What it Takes to Run a Biopharma Company
April 27, 2022
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Pharma: Striding Towards the Digital-only Reality with AI
November 21, 2021
As industries across the board move towards a digital-only world, pharma companies must account for the different technologies that are transforming the R&D process.